A clinical case of sporadic serous tubal intraepithelial carcinoma during surgical treatment for uterine myoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Moscow 117997, Ac. Oparina str. 4, Russia Background. The current concept of the pathogenesis of ovarian serous cancer and primary peritoneal serous carcinoma suggests the presence of prior serous tubal intraepithelial carcinoma (STIC). The basis for this statement is accumulated data on a concurrence of ovarian and primary peritoneal serous cancer and STIC. Furthermore, STIC is detected in women with BRCA1 and BRCA2 mutations after prophylactic adnexectomy. At the same time, there is information on STIC found in women with benign gynecologic disease. Description. The paper presents a clinical case of a 50-year-old patient whose histological examination of the material obtained during surgery for uterine myoma exhibited STIC on the left and minor serous carcinoma foci in the commissures on the surface of the right ovary. Immunohistological examination revealed the high expression of the markers Ki-67 and p53 in all tumor samples. Conclusion. Serous carcinoma foci in the commissures on the surface of the right ovary appear to be a highly aggressive primary peritoneal carcinoma, the precursor of which was STIC. Detailed histological examination of the fallopian tubes could reveal highly aggressive serous cancer at the preclinical stage in the patient with initially diagnosed benign lesion of the female reproductive system.

Full Text

Restricted Access

About the authors

Andrei I. Andreev

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: andreevxxx@mail.ru
PhD, Head of the pathogystology department

N. V Ivanova

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: Natalia.trubitzina@rambler.ru
PhD, Head of the gynecology department

O. V Aziev

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: Oaziev@yandex.ru
MD, Gynecologist of the gynecology department

L. N Shcherbakova

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: liya@post.com
PhD

V. O Porokhovoy

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: v_porohovoy@rambler.ru
Surgeon of the gynecology department

M. V Shamarakova

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: mshamarakova@yandex.ru
PhD, Pathologist of the pathohistology department

O. A Mogirevskaya

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: mogirevskaya@yandex.ru
PhD, Pathologist of the pathohistology department

A. V Asaturova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_asaturova@oparina4.ru
PhD, senior scientific researcher of department of anatomic pathology

L. S Ezhova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: l_ezhova@oparina4.ru
PhD, senior scientific researcher of department anatomic pathology

N. M Faizullina

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: n_faizullina@oparina4.ru
PhD, senior scientific researcher of department anatomic pathology

References

  1. Жордания К.И., Паяниди Ю.Г., Калиничева Е.В. Два пути развития серозного рака яичников. Онкогинекология. 2014; 3: 42-8
  2. Kurman R.J., Shih Ie.M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 2010; 34(3): 433-43.
  3. Карселадзе А.И. Некоторые проблемы клинической морфологии эпителиальных опухолей яичников. Практическая онкология. 2000; 1(4): 14-8. [Karseladze A.I. Some of the clinical problems of morphology of epithelial ovarian tumors. Prakticheskaya onkologiya. 2000; 1(4): 14-8. (in Russian)]
  4. Kurman R.J. Origin and molecular pathogenesis of ovarian high- grade serous carcinoma. Ann. Oncol. 2013; 24(Suppl. 10): x16-21.
  5. Kurman R.J., Shih Ie.M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 2011; 42(7): 918-31.
  6. Boyd C., McCluggage W.G. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with highх grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am. J. Surg. Pathol. 2012; 36(3): 368-75.
  7. Данилова Н.В., Андреева Ю.Ю., Королев А.В., Виноградов И.И., Завалишина Л.Э., Франк Г.А. Роль диспластических изменений эпителия маточной трубы в гистогенезе рака яичников. Архив патологии. 2014; 76(4): 9-14. [Danilova N.V., Andreeva Yu.Yu., Korolev A.V., Vinogradov I.I., Zavalishina L.E., Frank G.A. The role of dysplastic changes in the epithelium of the fallopian tube in the histogenesis of ovarian cancer. Arhiv patologii. 2014; 76(4): 9-14. (in Russian)]
  8. Sehdev A.S., Kurman R.J., Kuhn E., Shih Ie.M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod. Pathol. 2010; 23(6): 844-55.
  9. Jarboe E., Folkins A., Nucci M.R., Kindelberger D., Drapkin R., Miron A. et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 2008; 27(1): 1-9.
  10. Finch A., Shaw P., Rosen B., Murphy J., Narod S.A., Colgan T.J. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 2006; 100(1): 58-64.
  11. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E. et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 2007; 25(25): 3985-90.
  12. Kindelberger D.W., Lee Y., Mironetal A., Hirsch M.S., Feltmate C., Medeiros F. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31(2): 161-9.
  13. Dubernard G., Morice P., Rey A., Camatte S., Fourchotte V., Thoury A. et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur. J. Surg. Oncol. 2004; 30(9): 976-81.
  14. Schorge J.O., Muto M.G., Lee S.J., Huang L.W., Welch W.R., Bell D.A. et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 2000; 60(5): 1361-4.
  15. Choi C.H., Kim T.J., Kim W.Y., Ahn G.H., Lee J.W., Kim B.G. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol. Oncol. 2007; 105(3): 762-8.
  16. Асатурова А.В., Коган Е.А., Ежова Л.С., Жарков Н.В., Файзуллина Н.М., Хабас Г.Н. Папиллярная гиперплазия маточной трубы: сочетание с серозными пограничными опухолями яичника и молекулярнобиологическая характеристика. Акушерство и гинекология. 2015; 11: 58-64. [Asaturova A.V., Kogan E.A., Ezhova L.S., Zharkov N.V., Faizullina N.M., Khabas G.N. Papillary tubal hyperplasia: Concurrence with serous borderline ovarian tumors and molecular biological characteristics. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2015; (11): 58-64. (in Russian)]
  17. Kurman R.J., Vang R., Junge J., Hannibal C.G., Kjaer S.K., Shih Ie.M. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am. J. Surg. Pathol. 2011; 35(11): 1605-14.
  18. Kuhn E., Kurman R.J., Vang R., Sehdev A.S., Han G., Soslow R. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 2012; 226(3): 421-6.
  19. Yemelyanova A., Vang R., Kshirsagar M., Lu D., Marks M.A., Shih Ie.M. et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 2011; 24(9): 1248-53.
  20. Shahin M.S., Hughes J.H., Sood A.K., Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000; 89(9): 2006-17.
  21. Hashimoto T., Tokuchi Y., Hayashi M., Kobayashi Y., Nishida K., Hayashi S. et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 1999; 59(21): 5572-7.
  22. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010; 221(1): 49-56.
  23. Przybycin C.G., Kurman R.J., Ronnett B.M., Shin Ie.M., Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am. J. Surg. Pathol. 2010; 34(10):1407-16.
  24. Nasser S., Arsenic R., Lohneis P., Kosian P., Sehouli J. A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube. Anticancer Res. 2014; 34(1): 407-12.
  25. Seidman J.D., Zhao P., Yemelyanova A. “Primary peritoneal” high-grade serous carcinoma is likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol. Oncol. 2011; 120(3): 470-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies